Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
2.440
-0.070 (-2.79%)
At close: Aug 1, 2025, 4:00 PM
2.450
+0.010 (0.41%)
After-hours: Aug 1, 2025, 7:48 PM EDT
Editas Medicine Employees
Editas Medicine had 246 employees as of December 31, 2024. The number of employees decreased by 19 or -7.17% compared to the previous year.
Employees
246
Change (1Y)
-19
Growth (1Y)
-7.17%
Revenue / Employee
$145,679
Profits / Employee
-$1,021,264
Market Cap
204.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 246 | -19 | -7.17% |
| Dec 31, 2023 | 265 | 39 | 17.26% |
| Dec 31, 2022 | 226 | -38 | -14.39% |
| Dec 31, 2021 | 264 | 29 | 12.34% |
| Dec 31, 2020 | 235 | 27 | 12.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EDIT News
- 7 weeks ago - Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - GlobeNewsWire
- 2 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 2 months ago - Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript) - Seeking Alpha
- 2 months ago - Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June - GlobeNewsWire
- 2 months ago - Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 2 months ago - Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting - GlobeNewsWire
- 2 months ago - Editas Medicine Announces First Quarter 2025 Results and Business Updates - GlobeNewsWire
- 2 months ago - Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board - GlobeNewsWire